World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
139
Citations
109864
World Ranking
1719
National Ranking
986

Clifford A. Hudis publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Clifford A. Hudis sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 852 publications — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Clifford A. Hudis D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Clifford A. Hudis sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 139 D-Index — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Clifford A. Hudis is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a focus on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Genetics, and Radiology, Nuclear Medicine and Imaging.

The scientist's publication record includes significant research in breast cancer treatment and related topics. Their work covers a range of subjects such as Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Estrogen and related hormone effects, Cancer Risks and Factors, and Cancer survivorship and care.

Notable recent papers authored or co-authored by Clifford A. Hudis include:

  • "Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors," 2020, Nature Cancer
  • "Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial," 2023, The Lancet Oncology
  • "Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer," 2020, Journal of Clinical Oncology
  • "Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy," 2020, JNCI Journal of the National Cancer Institute
  • "ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106," 2020, Journal of Clinical Oncology

Frequent co-authors in their collaborative work include:

  • Eric P. Winer
  • Lisa A. Carey
  • Ann H. Partridge
  • Donald A. Berry
  • Constance Cirrincione

Hudis' publications have appeared in several venues, with substantial contributions to:

  • UNC Libraries
  • Journal of Clinical Oncology
  • Cancer Prevention Research
  • Clinical Cancer Research
  • Cancer Research

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Trastuzumab — Mechanism of Action and Use in Clinical Practice

    Clifford A. Hudis

  • Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

    Marc L. Citron;Donald A. Berry;Constance Cirrincione;Clifford Hudis

  • Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

    Ethan Basch;Allison M. Deal;Mark G. Kris;Howard I. Scher

  • Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience

    Andrew Seidman;Clifford Hudis;Mary Kathryn Pierri;Steven Shak

  • Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

    J. Baselga;Debasish Tripathy;J. Mendelsohn;S. Baughman

  • Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment

    Ethan Martin Basch;Allison M. Deal;Amylou C. Dueck;Howard I. Scher

  • Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

    Noah D. Kauff;Jaya M. Satagopan;Mark E. Robson;Lauren Scheuer

  • American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

    Eric P. Winer;Clifford Hudis;Harold J. Burstein;Antonio C. Wolff

  • ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

    Weiyi Toy;Yang Shen;Helen Won;Bradley Green

  • Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

    Kevin S. Hughes;Lauren A. Schnaper;Jennifer R. Bellon;Constance T. Cirrincione

  • Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer

    Kevin S. Hughes;Lauren A. Schnaper;Donald Berry;Constance Cirrincione

  • Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*

    Abram Recht;Stephen B. Edge;Lawrence J. Solin;David S. Robinson

  • American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

    Harold J. Burstein;Ann Alexis Prestrud;Jerome Seidenfeld;Holly Anderson

  • Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

    William M. Sikov;Donald A. Berry;Charles M. Perou;Baljit Singh

  • Dietary Fat Reduction and Breast Cancer Outcome: Interim Efficacy Results From the Women's Intervention Nutrition Study

    Rowan T. Chlebowski;George L. Blackburn;Cynthia A. Thomson;Daniel W. Nixon

  • Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

    Donald A. Berry;Constance Cirrincione;I. Craig Henderson;Marc L. Citron

Frequent Co-Authors

Larry Norton
Larry Norton Memorial Sloan Kettering Cancer Center
Eric P. Winer
Eric P. Winer Yale University
Andrew J. Dannenberg
Andrew J. Dannenberg Cornell University
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Donald A. Berry
Donald A. Berry The University of Texas MD Anderson Cancer Center
Lisa A. Carey
Lisa A. Carey University of North Carolina at Chapel Hill
Harold J. Burstein
Harold J. Burstein Harvard University
Monica Morrow
Monica Morrow Memorial Sloan Kettering Cancer Center
Edi Brogi
Edi Brogi Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn’t always mean attending a traditional MD program. Numerous asn to fnp bridge programs offer registered nurses a flexible route to becoming Family Nurse Practitioners—often entirely online.

For those interested in holistic health and preventive care, online nutrition degrees are a popular choice. These programs can open doors to careers in dietetics, wellness coaching, research, and public health.

If healthcare leadership interests you, many students choose cahme-accredited online mha programs. These degrees prepare graduates for managerial and executive roles in hospitals, clinics, and other healthcare organizations.

Finally, nurses looking to advance quickly without extra onsite clinicals are increasingly opting for rn to bsn programs. These programs enhance clinical knowledge and leadership skills—all online—making career advancement more accessible.

Exploring these online pathways lets students tailor their health careers to personal interests and schedules, making a rewarding future in medicine more attainable than ever.

Best Scientists Citing Clifford A. Hudis

Trending Scientists